Seagen and Zai Lab ink partnership on Tivdak expansion into China and surrounding areas; NC biotech snaps up seed funding

Zai Lab has signed on to commercialize Seagen and Genmab’s Tivdak — an ADC for recurrent or metastatic cervical cancer in patients in which chemotherapy isn’t working — in Mainland China, Hong Kong, Macau and Taiwan.

Seagen will get $30 million upfront, along with downstream milestone payments and tiered royalties….
Click here to view original post